Amarantus Bioscience Holdings, Inc. (AMBS) - OTCQX
  • Mon, Feb. 29, 11:45 AM
    • The European Patent Office issues an Intent to Grant a Patent notice to Amarantus BioScience Holdings (OTCQX:AMBS +7%) covering its mesencephalic-astrocyte-derived neurotrophic factor (MANF) method of use patent application titled "Method of Treatment for Retinal Disorders." The patent should be issued later this year.
    • MANF, discovered via the company's proprietary PhenoGuard Protein Discovery Engine, is a naturally occurring protein that reduces/prevents apoptosis (programmed cell death). It is under development for the treatment of retinitis pigmentosa, Wolfram's syndrome, retinal artery occlusion, Parkinson's disease and diabetes.
    | Mon, Feb. 29, 11:45 AM | 8 Comments
  • Wed, Feb. 10, 10:40 AM
    • The FDA designates Amarantus BioScience Holdings' (OTCQX:AMBS +11.1%) eltoprazine an Orphan Drug for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID).
    • Phase 2-stage eltoprazine, a small molecule neuromodulator, is a 5HT 1A/1B receptor agonist under development for PD-LID and adult attention deficit hyperactivity disorder (NASDAQ:ADHD).
    • PD-LID is an involuntary movement disorder that results from prolonged levodopa-based therapy, the standard-of-care for patients with Parkinson's disease. PD-LID occurs in as many as 80% of PD patients. It is difficult to treat and prevents patients from performing routine daily tasks.
    • Among the benefits of Orphan Drug status is a seven-year period of market exclusivity for the indication, if approved.
    • Previously: First patient dosed in Amarantus Bio's mid-stage study of eltoprazine in movement disorder (July 20, 2015)
    | Wed, Feb. 10, 10:40 AM
  • Sep. 14, 2015, 11:25 AM
    • The FDA designates Amarantus BioScience's (OTCQX:AMBS +9.3%) investigational mesencephalic-astrocyte-derived neurotrophic factor (MANF) an Orphan Drug for the treatment of retinal artery occlusion (RAO), a blockage of blood supply to the retina which leads to severe and sudden vision loss.
    • MANF, discovered via the company's proprietary PhenoGuard Protein Discovery Engine, is a naturally occurring protein that reduces/prevents apoptosis (programmed cell death). It is also under development for the treatment of retinitis pigmentosa, Wolfram's syndrome, Parkinson's disease and diabetes.
    • Among the benefits of Orphan Drug status is a seven-year period of market exclusivity for the indication, if approved.
    | Sep. 14, 2015, 11:25 AM | 7 Comments
  • Aug. 20, 2015, 10:12 AM
    • The USPTO issues U.S. Patent No. 9,115,208 to Amarantus BioScience Holdings (OTCQX:AMBS -0.7%) covering its MANF (mesencephalic-astrocyte-derived neurotrophic factor) protein therapy and cell therapy. The patent covers compositions of matter and methods of use related to the company's proprietary manufacturing process for synthetic MANF and its administration.
    • MANF's lead indication is retinitis pigmentosa. Other potential applications are retinal arterial occlusion, Wolfram's syndrome, Parkinson's disease and diabetes.
    | Aug. 20, 2015, 10:12 AM | 2 Comments
  • Jul. 20, 2015, 8:02 AM
    • Amarantus BioScience (OTCQX:AMBS) announces that the first patient has been dosed in its Phase 2b clinical trial assessing its lead product candidate, eltoprazine, for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID). Top-line results from the 60-subject, randomized, double-blind study are expected in H1 2016.  The estimated completion date of the study is December 2016.
    • Eltoprazine, a small molecule neuromodulator, is a 5HT 1A/1B receptor agonist under development for PD-LID and adult attention deficit hyperactivity disorder (ADHD).
    • PD-LID is an involuntary movement disorder that results from prolonged levodopa-based therapy, the standard-of-care for patients with Parkinson's disease. PD-LID occurs in as many as 80% of PD patients. It is difficult to treat and prevents patients from performing routine daily tasks.
    | Jul. 20, 2015, 8:02 AM
Company Description
We are a California based biopharmaceutical company founded in January 2008. We own or have exclusive licenses to various product candidates in the biopharmaceutical and diagnostic ares of the healthcare industry. We are developing our diagnostic product candidates in the field of neurology, and... More
Sector: Healthcare
Industry: Drug Manufacturers - Other
Country: United States